Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
about
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerNovel non-AR therapeutic targets in castrate resistant prostate cancerElevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancerDevelopment of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levelsPredicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database.Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate CancerNDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancerBiomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.Predicting bone scan positivity in non-metastatic castration-resistant prostate cancerManagement of bone metastases in refractory prostate cancer--role of denosumab.Unmet needs in the prediction and detection of metastases in prostate cancer.Wnt and Wnt inhibitors in bone metastasis.Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis.Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.Androgen-induced lncRNA POTEF-AS1 regulates apoptosis-related pathway to facilitate cell survival in prostate cancer cells.Beyond castration-defining future directions in the hormonal treatment of prostate cancer.Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancerThe utility of prostate-specific antigen in the management of advanced prostate cancer.Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.Nonmetastatic castration-resistant prostate cancer.Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.MTA1-activated Epi-microRNA-22 regulates E-cadherin and prostate cancer invasiveness.Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells.Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.Targeting the MLL complex in castration-resistant prostate cancer.Therapeutic management of bone metastasis in prostate cancer: an update.Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialSignificance of microRNAs in Androgen Signaling and Prostate Cancer Progression.Automated Bone Scan Index as Predictors of Survival in Prostate CancerLong non-coding RNAs and prostate cancer.
P2860
Q26783861-30410D5E-38F0-400F-A6D0-D31674313E7DQ27010542-12188016-BFED-4361-A55A-A6C2397EE961Q28383663-732D9BA2-84FF-4280-9EDE-54EA2CA2B639Q34032678-963990FB-BCEE-448C-9C1B-C0CAC9A9CB0FQ34406622-3D26F0F2-6DF7-42CF-B106-B995D9739EB2Q34536729-7BAE2CD8-3AA0-42A1-8ED5-29D16A22D2BCQ35372874-ABEA043A-F083-4EDB-BA6C-17225D7F485EQ35827731-FBCB2009-6C96-4B38-9278-3BB1554920D4Q36044706-D9E6372B-5555-4C4C-B155-30E825A4C6BCQ36056137-9ED30DF2-29E5-434E-9C5E-E0FF13AA6D50Q36056197-638B9268-4773-4B2E-9D6C-276CCE3D3D5BQ36216457-2930E335-CA10-4246-8860-271BAFDF3AD6Q36243296-E46E3B2B-BE1D-40F5-9341-E223A0B8E0D3Q36268971-1F55FF83-E434-4F08-8FE2-C4D56A1F7A47Q36283689-C379BD7F-3A7B-4E94-B13F-D441B8F13CE5Q36871680-EEF9B8AC-072E-489C-B6E6-D9C8A2A33956Q37056355-804DFEB7-00D7-4A5D-A71A-505904216713Q37078560-A5AF6488-F44A-49C9-A225-A8B7D7A5B576Q37227675-A32D1148-DF6C-4A79-A8B6-94A630763F6FQ37720488-87B659D3-FC0C-449A-B4B3-413657F70578Q37735619-3EB1B942-1849-4D64-B861-F42B1ABD17C0Q37962393-88AE1A4A-2DE0-4D8F-8551-6BC5E435CAAFQ38009942-392CDC3C-66A1-4D8C-BB6E-B070F90FD71AQ38119260-C18B0E4A-6280-43E8-906F-A1045EE376CFQ38145509-4FA2EE9D-7FDC-43F2-9855-B4D19CC3F122Q38306052-D71C4C5B-CE95-40A6-A3FB-CB647E1A0ACFQ38392787-B9FAEBF1-291F-46FC-9776-12DE6700BD22Q38640455-5745E4F2-4FB2-480D-9A94-6940D42A4424Q38680652-6D31F97E-A8D4-41C7-8B86-4DF212FD33A0Q38715226-22A1EC27-16F9-42B2-B1E4-16B2F61B4E7BQ38762346-47311BF1-52D2-46E3-91FC-3A33EF214DC3Q38779039-9AE72217-AB39-4AFF-A2C5-02A1BBB569FDQ38858948-FDF14FF3-5E67-4F65-ADD7-05004A1ACA75Q38893281-91CB6188-4B23-4615-A41C-C1F1545D1EC8Q38964037-6FEC04C3-89A4-44F3-9E88-DD77A19F6F05Q40112141-D3B7DA4F-4C71-471A-86C0-2F1F1DDBE7CBQ41489196-E49E1C4D-7C70-4224-A0ED-A48D7F18D6DAQ41552623-3798F443-6D84-4323-8E66-F0094FDA6E8AQ42376456-0BAD6EAA-B438-46DD-9B07-E2C0A82A7C65Q43061701-5D608ECA-35AF-4204-A3D3-60EC64CED650
P2860
Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Disease and host characteristi ...... nonmetastatic prostate cancer.
@en
type
label
Disease and host characteristi ...... nonmetastatic prostate cancer.
@en
prefLabel
Disease and host characteristi ...... nonmetastatic prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
Disease and host characteristi ...... nonmetastatic prostate cancer.
@en
P2093
Joel B Nelson
Ker-Ai Lee
Matthew R Smith
Richard Cook
P2860
P304
P356
10.1002/CNCR.25762
P407
P577
2010-11-16T00:00:00Z